Lavipharm S.A (LAVI) - Total Liabilities

Latest as of December 2024: €72.52 Million EUR ≈ $84.78 Million USD

Based on the latest financial reports, Lavipharm S.A (LAVI) has total liabilities worth €72.52 Million EUR (≈ $84.78 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LAVI shareholders equity momentum to track the company's year-over-year net asset growth rate.

Lavipharm S.A - Total Liabilities Trend (2014–2024)

This chart illustrates how Lavipharm S.A's total liabilities have evolved over time, based on quarterly financial data. See Lavipharm S.A free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Lavipharm S.A Competitors by Total Liabilities

The table below lists competitors of Lavipharm S.A ranked by their total liabilities.

Company	Country	Total Liabilities
DYNAGREEN EN.PR.GR.H YC 1 F:DYN	Germany	€13.25 Billion
Nuveen Core Plus Impact Fund NYSE:NPCT	USA	$186.76 Million
MFS Intermediate Income Trust NYSE:MIN	USA	$1.78 Million
Jiangsu Xinning Modern Logist SHE:300013	China	CN¥354.76 Million
Huitong Construction Group Co.Ltd. SHG:603176	China	CN¥4.71 Billion
Jack In The Box Inc NASDAQ:JACK	USA	$3.53 Billion
Altin Yunus Cesme Turistik Tesisler AS IS:AYCES	Turkey	TL1.52 Billion
Jiin Yeeh Ding Enterprise Co Ltd TWO:8390	Taiwan	NT$746.42 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Lavipharm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lavipharm S.A (LAVI) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.15	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lavipharm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lavipharm S.A (2014–2024)

The table below shows the annual total liabilities of Lavipharm S.A from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	€72.52 Million ≈ $84.78 Million	+0.70%
2023-12-31	€72.02 Million ≈ $84.19 Million	-2.54%
2022-12-31	€73.89 Million ≈ $86.39 Million	+17.89%
2021-12-31	€62.68 Million ≈ $73.28 Million	-0.42%
2020-12-31	€62.94 Million ≈ $73.58 Million	-1.38%
2019-12-31	€63.82 Million ≈ $74.62 Million	+3.90%
2018-12-31	€61.43 Million ≈ $71.81 Million	-5.10%
2017-12-31	€64.73 Million ≈ $75.67 Million	-19.09%
2016-12-31	€80.00 Million ≈ $93.53 Million	-45.50%
2015-12-31	€146.80 Million ≈ $171.62 Million	+10.55%
2014-12-31	€132.79 Million ≈ $155.24 Million	--

About Lavipharm S.A

AT:LAVI Greece Drug Manufacturers - Specialty & Generic

Market Cap

$281.03 Million

€240.38 Million EUR

Market Cap Rank

#14993 Global

#41 in Greece

Share Price

€1.42

Change (1 day)

-1.25%

52-Week Range

€0.78 - €1.70

All Time High

€2.05